ZA200410095B - Bioerodible film for ophthalmic drug delivery - Google Patents
Bioerodible film for ophthalmic drug delivery Download PDFInfo
- Publication number
- ZA200410095B ZA200410095B ZA200410095A ZA200410095A ZA200410095B ZA 200410095 B ZA200410095 B ZA 200410095B ZA 200410095 A ZA200410095 A ZA 200410095A ZA 200410095 A ZA200410095 A ZA 200410095A ZA 200410095 B ZA200410095 B ZA 200410095B
- Authority
- ZA
- South Africa
- Prior art keywords
- film
- film composition
- fatty acid
- acid glyceride
- soluble
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title claims description 37
- 239000003732 agents acting on the eye Substances 0.000 title description 5
- 229940023490 ophthalmic product Drugs 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 239000007943 implant Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 39
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 38
- 239000000194 fatty acid Substances 0.000 claims description 38
- 229930195729 fatty acid Natural products 0.000 claims description 38
- 229920000642 polymer Polymers 0.000 claims description 31
- 150000002148 esters Chemical class 0.000 claims description 20
- 229930012538 Paclitaxel Natural products 0.000 claims description 17
- 229960001592 paclitaxel Drugs 0.000 claims description 17
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 17
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
- 238000001356 surgical procedure Methods 0.000 claims description 11
- 208000010412 Glaucoma Diseases 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000001028 anti-proliverative effect Effects 0.000 claims description 7
- 230000000149 penetrating effect Effects 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 12
- 239000007787 solid Substances 0.000 abstract 2
- 150000002634 lipophilic molecules Chemical class 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 208000002352 blister Diseases 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 239000012738 dissolution medium Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 4
- QHZLMUACJMDIAE-SFHVURJKSA-N 1-hexadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO QHZLMUACJMDIAE-SFHVURJKSA-N 0.000 description 3
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 3
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 3
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 3
- QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000008389 polyethoxylated castor oil Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- CLRCAFAXMVNJRH-UHFFFAOYSA-N 2,3-dihydroxypropyl tridecanoate Chemical compound CCCCCCCCCCCCC(=O)OCC(O)CO CLRCAFAXMVNJRH-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 235000012093 Myrtus ugni Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Chemical class 0.000 description 1
- 229920001214 Polysorbate 60 Chemical class 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 244000061461 Tema Species 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- BFMKFCLXZSUVPI-UHFFFAOYSA-N ethyl but-3-enoate Chemical compound CCOC(=O)CC=C BFMKFCLXZSUVPI-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Chemical class 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Chemical class 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical class O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39584002P | 2002-07-15 | 2002-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200410095B true ZA200410095B (en) | 2006-07-26 |
Family
ID=30115932
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200410095A ZA200410095B (en) | 2002-07-15 | 2004-12-14 | Bioerodible film for ophthalmic drug delivery |
| ZA200410096A ZA200410096B (en) | 2002-07-15 | 2004-12-14 | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200410096A ZA200410096B (en) | 2002-07-15 | 2004-12-14 | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7678827B2 (ja) |
| EP (1) | EP1521573B1 (ja) |
| JP (1) | JP4463681B2 (ja) |
| KR (1) | KR101003518B1 (ja) |
| CN (1) | CN100355455C (ja) |
| AT (1) | ATE382330T1 (ja) |
| AU (1) | AU2003248777B2 (ja) |
| BR (1) | BR0312635A (ja) |
| CA (1) | CA2491313C (ja) |
| CY (1) | CY1107166T1 (ja) |
| DE (1) | DE60318446T2 (ja) |
| DK (1) | DK1521573T3 (ja) |
| ES (1) | ES2295647T3 (ja) |
| MX (1) | MXPA05000632A (ja) |
| PL (1) | PL206594B1 (ja) |
| PT (1) | PT1521573E (ja) |
| WO (1) | WO2004006890A1 (ja) |
| ZA (2) | ZA200410095B (ja) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6955661B1 (en) * | 1999-01-25 | 2005-10-18 | Atrium Medical Corporation | Expandable fluoropolymer device for delivery of therapeutic agents and method of making |
| US7947015B2 (en) * | 1999-01-25 | 2011-05-24 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| CA2491313C (en) * | 2002-07-15 | 2011-05-24 | Alcon, Inc. | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
| US20070184089A1 (en) * | 2002-07-15 | 2007-08-09 | Alcon, Inc. | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| JP5097883B2 (ja) * | 2004-09-02 | 2012-12-12 | 株式会社 神崎高級工機製作所 | 油圧駆動車両 |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| WO2006036969A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Formation of barrier layer |
| DE602006005826D1 (de) * | 2005-09-21 | 2009-04-30 | Univ Aston | Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primärem glaukom |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9173773B2 (en) * | 2006-06-21 | 2015-11-03 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
| US9474645B2 (en) * | 2006-06-21 | 2016-10-25 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
| US20080045911A1 (en) * | 2006-06-21 | 2008-02-21 | Borgia Maureen J | Punctal plugs for the delivery of active agents |
| UY30883A1 (es) | 2007-01-31 | 2008-05-31 | Alcon Res | Tapones punctales y metodos de liberacion de agentes terapeuticos |
| NZ598483A (en) * | 2007-09-07 | 2013-08-30 | Quadra Logic Tech Inc | Drug cores for sustained release of therapeutic agents |
| TWI498136B (zh) * | 2007-10-09 | 2015-09-01 | Alcon Res Ltd | 用於遞送速率及溫度相依性物質至眼睛的注射器及其製備方法 |
| TWI451862B (zh) * | 2007-10-09 | 2014-09-11 | Alcon Res Ltd | 用於眼睛注射的熱係數驅動藥丸尺寸 |
| JP2010104632A (ja) | 2008-10-31 | 2010-05-13 | Hoya Corp | ゲル化能を有する眼科用組成物 |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US8372036B2 (en) * | 2009-05-06 | 2013-02-12 | Alcon Research, Ltd. | Multi-layer heat assembly for a drug delivery device |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| CN102724951A (zh) | 2009-11-09 | 2012-10-10 | 阿勒根公司 | 用于刺激毛发生长的组合物和方法 |
| US8177747B2 (en) * | 2009-12-22 | 2012-05-15 | Alcon Research, Ltd. | Method and apparatus for drug delivery |
| LT2515887T (lt) * | 2009-12-22 | 2018-08-10 | Ucb Biopharma Sprl | Polivinilpirolidonas, skirtas nekristalinės rotigotino formos kietos dispersijos stabilizavimui |
| US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
| DE102011016277B4 (de) | 2011-04-06 | 2013-02-21 | Heraeus Medical Gmbh | Plastisch verformbares, biodegradierbares Hämostyptikum und Verfahren zum Formen eines solchen |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| EP2956096A1 (en) | 2013-02-15 | 2015-12-23 | Allergan, Inc. | Sustained drug delivery implant |
| TW201601717A (zh) * | 2013-09-26 | 2016-01-16 | 參天製藥股份有限公司 | 含有經安定化之２－胺基－３－（４－溴苯甲醯基）苯基醋酸之水性組成物 |
| AU2015266850B2 (en) | 2014-05-29 | 2019-12-05 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| AU2017252294B2 (en) | 2016-04-20 | 2021-12-02 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
| CA3038115A1 (en) * | 2016-09-30 | 2018-04-05 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
| US10806566B2 (en) | 2017-06-13 | 2020-10-20 | Alcon Inc. | Intraocular lens compositions |
| RU2675691C1 (ru) * | 2017-09-14 | 2018-12-21 | Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации | Способ длительной перфузии субтенонового пространства лекарственными средствами |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| JPS6042766B2 (ja) | 1978-12-09 | 1985-09-25 | 日本化薬株式会社 | 基剤 |
| US4797288A (en) | 1984-10-05 | 1989-01-10 | Warner-Lambert Company | Novel drug delivery system |
| GB8524421D0 (en) | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| JP2893191B2 (ja) | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
| US5015474A (en) * | 1988-11-22 | 1991-05-14 | Parnell Pharmaceuticals, Inc. | Composition for imparting moisture to a substrate |
| EP0458894B1 (en) * | 1989-02-17 | 1996-05-15 | The Liposome Company, Inc. | Lipid excipient for nasal delivery and topical application |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5660851A (en) | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
| JPH05507683A (ja) | 1990-04-27 | 1993-11-04 | アラーガン、インコーポレイテッド | ポリマードラッグデリバリーシステム |
| IE65045B1 (en) | 1990-04-28 | 1995-10-04 | Takeda Chemical Industries Ltd | Granulated preparations and method of producing the same |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| HU219242B (en) | 1991-05-13 | 2001-03-28 | Boots Co Plc | S(+)-ibuprofen sodium salt dihydrate, pharmaceutical composition comprising this compound and process for production of them |
| US5629019A (en) * | 1992-02-27 | 1997-05-13 | Alza Corporation | Formulations with hydrophobic permeation enhancers |
| US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| AU5092493A (en) | 1992-09-08 | 1994-03-29 | Allergan, Inc. | Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5433951A (en) | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5773021A (en) | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
| CA2119109C (en) | 1994-03-15 | 2002-11-12 | Florian Gurtler | Bioadhesive ophthalmic insert |
| PT754032E (pt) | 1994-04-08 | 2002-05-31 | Atrix Lab Inc | Composicoes liquidas para difusao |
| US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
| US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
| AUPM897594A0 (en) | 1994-10-25 | 1994-11-17 | Daratech Pty Ltd | Controlled release container |
| PT788351E (pt) | 1994-11-10 | 2003-06-30 | Univ Kentucky Res Foundation T | Dispositivo implantavel recarregavel de libertacaocontrolada para administrar medicamentos direc tamente numa porcao interna do corpo |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| US5718922A (en) | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6162801A (en) | 1995-11-20 | 2000-12-19 | Kita; Kiyoshi | External ophthalmic preparation containing vitamin D |
| US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| WO1998040051A1 (en) * | 1997-03-12 | 1998-09-17 | Abbott Laboratories | Lipophilic binary systems for the administration of lipophilic compounds |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| CA2300154C (en) | 1997-08-11 | 2008-07-08 | Allergan Sales, Inc. | Sterile bioerodible implant device with improved biocompatability and method |
| IL121647A (en) * | 1997-08-28 | 2001-07-24 | Pharmateam Dev Ltd | Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate |
| US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
| US6099853A (en) * | 1997-09-04 | 2000-08-08 | Protein Express | Vaginal suppository vaccine for urogenital infections |
| US5891476A (en) * | 1997-12-22 | 1999-04-06 | Reo; Joe P. | Tastemasked pharmaceutical system |
| DE19804310A1 (de) * | 1998-02-04 | 1999-08-05 | Aventis Res & Tech Gmbh & Co | Spiroverbindungen und deren Verwendung |
| DE10030378A1 (de) * | 2000-06-21 | 2002-03-14 | Audit Inst For Medical Service | Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen |
| WO2001097832A1 (de) * | 2000-06-21 | 2001-12-27 | Audit Institute For Medical Services And Quality Assurance Gmbh | Pharmazeutische zubereitungen enthaltend cyclosporine und neutralöle |
| AR038628A1 (es) | 2002-03-04 | 2005-01-19 | Novartis Ag | Composicion oftalmica |
| CA2491313C (en) * | 2002-07-15 | 2011-05-24 | Alcon, Inc. | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
-
2003
- 2003-06-30 CA CA2491313A patent/CA2491313C/en not_active Expired - Fee Related
- 2003-06-30 MX MXPA05000632A patent/MXPA05000632A/es active IP Right Grant
- 2003-06-30 PT PT03764334T patent/PT1521573E/pt unknown
- 2003-06-30 DE DE60318446T patent/DE60318446T2/de not_active Expired - Lifetime
- 2003-06-30 EP EP03764334A patent/EP1521573B1/en not_active Expired - Lifetime
- 2003-06-30 WO PCT/US2003/020707 patent/WO2004006890A1/en active IP Right Grant
- 2003-06-30 DK DK03764334T patent/DK1521573T3/da active
- 2003-06-30 JP JP2004521511A patent/JP4463681B2/ja not_active Expired - Fee Related
- 2003-06-30 US US10/610,435 patent/US7678827B2/en not_active Expired - Fee Related
- 2003-06-30 AU AU2003248777A patent/AU2003248777B2/en not_active Ceased
- 2003-06-30 BR BR0312635-8A patent/BR0312635A/pt not_active IP Right Cessation
- 2003-06-30 PL PL374743A patent/PL206594B1/pl not_active IP Right Cessation
- 2003-06-30 ES ES03764334T patent/ES2295647T3/es not_active Expired - Lifetime
- 2003-06-30 KR KR1020057000488A patent/KR101003518B1/ko not_active IP Right Cessation
- 2003-06-30 AT AT03764334T patent/ATE382330T1/de active
- 2003-06-30 CN CNB038167913A patent/CN100355455C/zh not_active Expired - Fee Related
-
2004
- 2004-12-14 ZA ZA200410095A patent/ZA200410095B/en unknown
- 2004-12-14 ZA ZA200410096A patent/ZA200410096B/en unknown
-
2008
- 2008-01-31 CY CY20081100111T patent/CY1107166T1/el unknown
- 2008-06-03 US US12/132,003 patent/US8178576B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1521573A1 (en) | 2005-04-13 |
| US20040013704A1 (en) | 2004-01-22 |
| US20080241224A1 (en) | 2008-10-02 |
| EP1521573B1 (en) | 2008-01-02 |
| US7678827B2 (en) | 2010-03-16 |
| ES2295647T3 (es) | 2008-04-16 |
| DE60318446D1 (de) | 2008-02-14 |
| ZA200410096B (en) | 2006-07-26 |
| KR20050023409A (ko) | 2005-03-09 |
| AU2003248777B2 (en) | 2008-02-14 |
| MXPA05000632A (es) | 2005-03-31 |
| JP2006500328A (ja) | 2006-01-05 |
| PL374743A1 (en) | 2005-10-31 |
| AU2003248777A1 (en) | 2004-02-02 |
| PL206594B1 (pl) | 2010-08-31 |
| KR101003518B1 (ko) | 2010-12-30 |
| DK1521573T3 (da) | 2008-03-25 |
| BR0312635A (pt) | 2005-04-19 |
| WO2004006890A1 (en) | 2004-01-22 |
| CA2491313C (en) | 2011-05-24 |
| DE60318446T2 (de) | 2008-05-21 |
| JP4463681B2 (ja) | 2010-05-19 |
| US8178576B2 (en) | 2012-05-15 |
| CA2491313A1 (en) | 2004-01-22 |
| ATE382330T1 (de) | 2008-01-15 |
| CN100355455C (zh) | 2007-12-19 |
| PT1521573E (pt) | 2008-02-08 |
| CY1107166T1 (el) | 2012-10-24 |
| CN1668277A (zh) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200410095B (en) | Bioerodible film for ophthalmic drug delivery | |
| CA2491312C (en) | Bioerodible film for ophthalmic drug delivery | |
| CA2838526C (en) | Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer | |
| AU2014360184B2 (en) | Intracameral implant for treatment of an ocular condition | |
| JP5696121B2 (ja) | α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント | |
| AU2007223057B2 (en) | Ocular therapy using sirtuin-activating agents | |
| JP2007535367A (ja) | エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法 | |
| US11116776B2 (en) | Intravitreal drug delivery systems for the treatment of ocular conditions | |
| EP3967297A1 (en) | Sustained release latanoprost implant | |
| CN102497865A (zh) | 用于治疗眼部病症的眼内缓释药物递送系统和方法 | |
| JP2013126997A (ja) | β−アドレナリン受容体拮抗薬を含む持続放出眼内インプラント | |
| JP2007535564A (ja) | 抗興奮毒性剤持続放出眼内インプラントおよび関連方法 | |
| Deshpande et al. | Bioerodible polymers for ocular drug delivery | |
| US20040197340A1 (en) | Pharmaceutical composition based on macrolides for topical application in ophthalmology | |
| US20060134174A1 (en) | Pharmaceutical delivery system and method of use | |
| AU2011239238B2 (en) | Ocular therapy using sirtuin-activating agents |